Indication

Pulmonary arterial hypertension

Pulmonary arterial hypertension is a rare, progressive cardiovascular disorder classified as Group 1 pulmonary hypertension that affects the precapillary pulmonary arterial vasculature. Read more about Pulmonary arterial hypertension

135 drugs 68 manufacturers

Advertisement

Drugs that treat it

Common Pulmonary arterial hypertension therapies.

Showing 64–72 of 135 drugs

BOSENTAN

PULMONARY ARTERIAL HYPERTENSION
COTHERIX, INC.

BOSENTAN

PAH AGENTS- ENDOTHELIN RECEPTOR ANTAGONISTS·PULMONARY ARTERIAL HYPERTENSION
Actavis Pharma

BOSENTAN

PULMONARY ARTERIAL HYPERTENSION
Hikma Pharmaceuticals USA

TREPROSTINIL SODIUM

PULMONARY ANTIHYPERTENSIVE AGENTS - PROSTACYCLIN-TYPE·PULMONARY ARTERIAL HYPERTENSION
Teva Parenteral Medicines

AMBRISENTAN

PULMONARY ARTERIAL HYPERTENSION
PAR HEALTH USA,

AMBRISENTAN

PAH AGENTS- ENDOTHELIN RECEPTOR ANTAGONISTS·PULMONARY ARTERIAL HYPERTENSION
Mylan Pharmaceuticals

AMBRISENTAN

PAH AGENTS- ENDOTHELIN RECEPTOR ANTAGONISTS·PULMONARY ARTERIAL HYPERTENSION
SUN PHARMA GLOB

AMBRISENTAN

PAH AGENTS- ENDOTHELIN RECEPTOR ANTAGONISTS·PULMONARY ARTERIAL HYPERTENSION
SIGMAPHARM LABO

AMBRISENTAN

PAH AGENTS- ENDOTHELIN RECEPTOR ANTAGONISTS·PULMONARY ARTERIAL HYPERTENSION
CIPLA USA, INC.
Filter & compare in the drug finder →Opens the drug finder with Pulmonary arterial hypertension preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Pulmonary arterial hypertension.

Pulmonary arterial hypertension is a rare, progressive cardiovascular disorder classified as Group 1 pulmonary hypertension that affects the precapillary pulmonary arterial vasculature.

It is characterized by pathological vascular remodeling, vasoconstriction, endothelial cell proliferation, and thrombosis within the small pulmonary arteries.

These structural changes progressively elevate pulmonary vascular resistance and arterial pressure, increasing right ventricular afterload and eventually leading to right-sided heart failure and death.

Patients typically present with exertional dyspnea, fatigue, chest pain, syncope, and peripheral edema, and the condition can arise idiopathically, heritably, or secondary to connective tissue diseases, congenital heart defects, or certain drugs and toxins.

Personalize your experience

Follow Pulmonary arterial hypertension and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it